U.S. Markets close in 6 hrs 10 mins

Curis, Inc. (CRIS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.70-0.04 (-2.30%)
As of 9:49AM EDT. Market open.
People also watch
  • Yes, it is old news, but impressive (all the information at 03/31/2017... tons of shares bought by Institutions):

    FMR LLC 03/31/2017 15,131,961 393,582 2.67 25,270
    BLACKROCK INC. 03/31/2017 9,181,022 9,173,474 121,535.16 15,332
    MILLENNIUM MANAGEMENT LLC 03/31/2017 2,272,318 1,078,340 90.32 3,795
    VANGUARD GROUP INC 03/31/2017 4,827,625 304,268 6.73 8,062
    CORMORANT ASSET MANAGEMENT, LLC 03/31/2017 2,000,000 (410,900) (17.04) 3,340
    STATE STREET CORP 03/31/2017 1,681,620 17,640 1.06 2,808
    POLAR CAPITAL LLP 03/31/2017 1,641,176 121,050 7.96 2,741
    NORTHERN TRUST CORP 03/31/2017 1,285,369 29,758 2.37 2,147
    ADAGE CAPITAL PARTNERS GP, L.L.C. 03/31/2017 1,040,000 5,000 .48 1,737
    GEODE CAPITAL MANAGEMENT, LLC 03/31/2017 918,592 70,139 8.27 1,534
    ROYAL BANK OF CANADA 03/31/2017 912,296 44,290 5.10 1,524
    D. E. SHAW & CO., INC. 03/31/2017 772,320 66,250 9.38 1,290
    POINT72 ASSET MANAGEMENT, L.P. 03/31/2017 500,400 500,400 New 836
    PERCEPTIVE ADVISORS LLC 03/31/2017 500,000 500,000 New 835
    AMERIPRISE FINANCIAL INC 03/31/2017 476,773 (27,674) (5.49) 796
    TIAA CREF INVESTMENT MANAGEMENT LLC 03/31/2017 470,027 (76,584) (14.01) 785
    DEUTSCHE BANK AG\ 03/31/2017 407,642 (130,434) (24.24) 681
  • Like Otis, I am sitting on the dock of the bay watching the Curis ship roll in and then roll away. Right now Curis lost at sea, but after listening again to March 9th earnings conference call, regarding 907 Curis ship will start rolling back in starting with Jefferies conference in early June. If 907 interim data is positive to the point that Curis seeks meeting with FDA, then stock should jump back to 3. If Cris indicates it will not disclose data until after getting FDA go ahead, and earliest news is announcement that FDA has given CRIS green light for conversion to pivotal, then a buyer now will have doubled his or her money by end of summer. If CA-170 news is positive, then the price triples.
  • This POS stock doesn't move for anything when the NASDAQ is moving higher but, always seems to sink when the market is selling off.

    Ali and this management are the worst POS ever!
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states:
    • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence late 2017
    • Sales and or licensing agreement/s could be very significant and fast
    • Company is now commercializing several other disruptive products in large markets



    Clyra Medical | Make Life Better
  • Looks like the next time the 13-F's are released, there will probably be a lot less investors holding CRIS
  • McNab is probably dumping every last share now that hes not chairman anymore. This is the worst management team in biotech. $1 billion in losses and these incompetent a-holes are still destroying shareholders daily. Corrupt corrupt corrupt
  • Probably more #$%$ management selling shares!
  • What the heck is going on?
  • Welcome to the Casino. Yesterday +7%. Today -9%. ¿¿¿???
    Who bought yesterday all the day between 2.10 and 2.18?

    Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

    Abstract TPS3099

    James J. Lee, MD, PhD - First Author •
    University of Pittsburgh Cancer Institute
    Poster Board: #190a
  • No new SEC filing today. It confirms that McNab did the last sell on Friday 5th, as I suggested some days ago. This is good news.
  • Ali is such a wonderful CEO LOL.. what losers
  • Is McNab buying back his shares? Nice to the volume up.
  • pps down and down. But Institucional holdings increased. Now Blackrock:
    BLACKROCK INC. 03/31/2017 9,181,022 9,173,474 121,535.16 17,536
  • Conference call disclosed that NcNab's selling of his shares was automatic in light of his retirement from the board. So I am assuming nothing adverse about the future of CRIS should be drawn from his decision to retire and the concomitant selling of his shares. On the drug development front, we learned only that CRIS will disclose preliminary phase1 data in the second half of 2017, not the early part of the second half as promised in March. So that means December 31st. Nothing new about 907 except the Baird analyst did not know that the much hoped for expansion from 60 to 100 patients was for MYC altered only. Cris still has not been able to enroll the initial 60 patients from which it hopes to get sufficient positive data so it can then go to the FDA and get approval to expand to 100 for the purpose of get on a registration path. A really uninspiring conference as compared to the last one where there were more analysts on the line and the company was more upbeat about the prospect of 907. I expect the stock to go below $2.
  • NASDAQ screams higher while clinical stage biotech stocks are being sold. CRIS is one of the garbage stocks that traders are dumping
  • As I said, we have a new selling filing from McNab.
    On Wed sold 30,000
    on Thursday 30,100
    and today sold 16,176.

    As JR & MW McNab Operating LP now have 50,000 shares (exact 50,000 and today sold 16,176), WE CAN DEDUCT THAT THE SELLING ACTIVITY FINISHED TODAY. THIS IS GREAT NEWS THINKING ON MONDAY AND THE FUTURE.
  • Relax, McNab Jr. selling is a non event, he"s on auto sell. If 907 shows results, big pharma will start calling. If 170 shows up, bet the farm.
  • You can read in twitter about CRIS: "garbage", "toilet", etc. etc.

    Those words mean the exact moment when many people get depressed.

    The time to buy has arrived.
  • Does Novartis' experimental drug threaten to undercut CUDC-907?
    "Novartis plans additional filings for CTL019 in the US and EU markets later this year, including a BLA with the FDA for treatment of adults with r/r diffuse large B-cell lymphoma (DLBCL) and applications for marketing authorization with the European Medicines Agency in r/r B-cell ALL and r/r DLBCL."